Porównanie stężeń chromograniny A (CgA) w surowicy i w osoczu (EDTA2K) oraz odnośnych zakresów referencyjnych u zdrowych mężczyzn by Glinicki, Piotr et al.
53
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.2015.0009
Tom/Volume 66; Numer/Number 1/2015
ISSN 0423–104X
Piotr Glinicki M.Sc., Ph.D., Department of Endocrinology, The Centre of Postgraduate Medical Education, Bielański Hospital, Cegłowska 80,  
01–809 Warsaw, Poland, tel.: +48 22 569 02 93, fax: +48 22 834 31 31, e-mail: glinicki@cmkp.edu.pl
Comparison of chromogranin A (CgA) levels in serum  
and plasma (EDTA2K) and the respective reference ranges  
in healthy males
Porównanie stężeń chromograniny A (CgA) w surowicy i w osoczu (EDTA2K)  
oraz odnośnych zakresów referencyjnych u zdrowych mężczyzn
Piotr Glinicki, Wojciech Jeske, Renata Kapuścińska, Wojciech Zgliczyński 
Department of Endocrinology, The Centre of Postgraduate Medical Education, Warsaw, Poland
Abstract
Introduction: Chromogranin A (CgA) is a major, nonspecific marker of neuroendocrine tumours (NET). There are a few routinely used 
assays for the measurement of CgA concentration in serum or plasma. These assays differ in analytical techniques (radioimmunoassay, 
ELISA, CLIA, TRACE), have different calibrators, and use different antibodies which recognise different epitopes of CgA molecule.
Our study was designed to confirm the noted earlier differences in CgA levels measured in serum and plasma, and to establish respective 
reference ranges in a group of healthy males. 
Material and methods: In 145 male blood donors (age 19–61 years, mean = 35.7), blood was collected into two tubes: one with EDTA2K 
(plasma) and one with clot activator (serum). Chromogranin A was measured by immunoradiometric kit (CIS bio, France).
Results: In blood donors, the median (and the range) of CgA concentration were as follows for serum samples — 42.0 ng/mL (16–108 ng/mL) 
and for plasma (EDTA2K) samples — 58.0 ng/mL (23–153 ng/mL). The differences between serum and plasma ranged 15–75% (median 
26%). Plasma CgA levels were significantly higher in relation to serum CgA levels (p < 0.0001). Correlation of CgA in serum and plasma 
was r = 0.8493; p < 0.01. The reference ranges for CgA measured in serum and plasma in males, expressed as 2.5 to 97.5 percentiles, were: 
21.0–108.0 ng/mL and 31.0–153.0 ng/mL respectively.
Conclusions:
1. Significant differences in the concentrations of CgA measured in plasma and in serum demand the application of separate reference 
ranges adjusted to the type of investigated material.
2. Each laboratory should recommend only one sort of sample material for CgA assay. 
(Endokrynol Pol 2015; 66 (1): 53–56)
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Streszczenie
Wstęp: Chromogranina A (CgA) jest głównym, niespecyficznym markerem guzów neuroendokrynnych (NET). Istnieje kilka rutynowych 
testów służących do oznaczania stężenia CgA w surowicy i w osoczu. Testy te różnią się techniką analityczną (izotopowe, ELISA, CLIA, 
TRACE), są różnie kalibrowane, użyto w nich różne przeciwciała rozpoznające odmienne epitopy na powierzchni cząsteczki CgA.
Badanie miało na celu potwierdzenie zaobserwowanych wcześniej różnic w mierzonym stężeniu CgA w surowicy i w osoczu oraz usta-
lenie odpowiednich zakresów referencyjnych w grupie zdrowych mężczyzn.
Materiał i metody: U 145 krwiodawców płci męskiej w wieku 19–61 lat (średnia wieku = 35,7) pobierano krew do 2 probówek: jednej 
z EDTA2K (osocze) i jednej z aktywatorem wykrzepiania (surowica). Stężenie CgA było oznaczane metodą immunoradiometryczną (CIS 
bio, Francja).
Wyniki: U dawców krwi, mediana oraz zakres stężeń CgA były następujące: dla surowicy — 42,0 ng/ml (16–108 ng/ml), a dla osocza 
(EDTA2K) — 58,0 ng/ml (23–153 ng/ml). Różnice między surowicą a osoczem wyniosły 15–75% (mediana 26%). Stężenie CgA było istotnie 
statystycznie wyższe w osoczu niż w surowicy (p < 0,0001). Korelacja stężenia CgA w surowicy i w osoczu wyniosła r = 0,8493; p < 0,01. 
Zakresy referencyjne CgA oznaczanej w surowicy i w osoczu u mężczyzn wyrażone jako 2,5–97,5 percentyla wyniosły odpowiednio: 
21,0–108,0 ng/ml oraz 31,0–153,0 ng/ml. 
Wnioski:
1. Istnieją istotne różnice w stężeniu CgA mierzonej w surowicy i w osoczu, zatem uzyskiwane wyniki powinny być odnoszone do 
osobnych zakresów referencyjnych odpowiadających rodzajowi użytego materiału do badania.
2. Każde laboratorium powinno zalecać stosowanie tego samego rodzaju materiału do oznaczenia stężenia CgA.
(Endokrynol Pol 2015; 66 (1): 53–56)
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ng/mL. According to the kit producer, the reference value 
for serum sample was 19.4–98.1 ng/mL, with the median 
at 41.6 ng/mL. Intra-assay coefficients of variation (CV) 
were: 6% for 30 ng/mL, 3.8% for 144 ng/mL, and 2.2% for 
996 ng/mL. Inter-assay CV values were: 8.5% for 29 ng/mL, 
5.7% for 144 ng/mL and 5.3% for 996 ng/mL. 
This study was approved by the Bioethics Commit-
tee of The Centre of Postgraduate Medical Education.
Data is presented as median (and the range) and 
mean ± SD. Normality of the distribution was stud-
ied by the Shapiro-Wilk test. Distribution of results 
differs from the theoretical normal distribution. The 
Wilcoxon’s signed-rank test was performed to estimate 
differences between groups. The relationship between 
the compared results was expressed using Spearman’s 
rank correlation analysis. The reference ranges were 
expressed as 2.5 to 97.5 percentiles. A p-value of < 0.05 
was considered to be significant and p < 0.01 highly 
significant. All statistical analyses were performed using 
statistical software (PQStat ver. 1.4.2.324). 
Results
In blood donors, the median (and the range) of CgA 
concentration determined for serum samples was 
42.0 ng/mL (16-108 ng/mL) and for plasma samples was 
58.0 ng/mL (23-153 ng/mL). The differences between 
serum and plasma ranged from 15% to 79% (median 
26%) (Table I). Plasma CgA levels were significantly 
higher in relation to serum CgA levels (p < 0.0001) 
(Fig. 1). Correlation of CgA in serum and plasma was 
r = 0.8493; p < 0.01 (Fig 2). The determined reference 
ranges for CgA measured in serum and plasma in males 
expressed as 2.5 to 97.5 percentile were: 21.0–108.0 ng/mL 
and 31.0–153.0 ng/mL respectively (Table II). 
Discussion
Chromogranin A (CgA) is known as the most useful 
nonspecific biomarker of various types of neuroendocrine 
tumours. Currently, several commercial methods allow 
determination of CgA concentrations in blood. These 
assays differ in analytical techniques, have different cali-
brators, and use different antibodies which recognise dif-
Introduction
Chromogranin A (CgA) is an acid hydrophilic protein 
that belongs to the chromogranin/secretogranin fam-
ily. Human CgA is a 439 amino acids protein (48kDa) 
localised in the dense core secretory granules of many 
normal and neoplastic neuroendocrine cells of the 
diffuse neuroendocrine system (DES), and endocrine 
cells of the endocrine glands (e.g. pancreatic islets). CgA 
plays an important role in intracellular and extracellular 
function of endocrine and neuroendocrine cells [1, 2]. 
CgA has become a main, nonspecific marker of neuroen-
docrine tumours (NET) because it is secreted by most 
NETs, particularly GEP-NET (gastroenteropancreatic 
neuroendocrine tumours), midgut carcinoids, pancre-
atic tumours and pheochromocytoma [3, 4].
There are few routinely used assays for the measure-
ment of CgA concentration in serum or plasma. These 
assays have different analytical techniques (radioim-
munoassay, ELISA, CLIA, TRACE), have different cali-
brators, and use different antibodies which recognise 
different epitopes of CgA molecule [5]. 
Our study was designed to confirm the noted ear-
lier differences in CgA levels measured in serum and 
plasma, and to establish the respective references ranges 
in a group of healthy males. 
Material and methods
145 male blood donors (age mean ± SD 35.7 ± 9.4; range 
19–61 years) were investigated. The following exclusion 
criteria in our study were settled: treatment with proton 
pump inhibitors, histamine H2-receptors blockers, cor-
ticosteroids, presence of some chronic diseases such as 
impaired renal or hepatic function, inflammatory bowel 
diseases, and prostate cancer. At each collection, blood was 
withdrawn into two tubes: one with EDTA2K (plasma) 
and one with clot activator (serum). After blood collection, 
venous blood was centrifuged (10 minutes, 3,500 rpm) 
and plasma (EDTA2K) and serum samples were frozen at 
–30°C and stored until assayed. 
Chromogranin A was measured by immunoradio-
metric kit (IRMA) (CGA-RIA CT, CIS bio International, 
Gif-sur-Ivette cedex, France). Analytical sensitivity was 1.5 
Table I. Comparison of the CgA median (and the range) and mean ± SD in serum and plasma (EDTA2K) in healthy males
Tabela I. Porównanie median (oraz zakresów) i średnich ± SD w surowicy i w osoczu (EDTA2K) u zdrowych mężczyzn
Serum [ng/mL] (n = 145) Plasma (EDTA2K) [ng/mL] (n = 145)
Median Range Mean SD Median Range Mean SD
42.0 16–108 45.7 15.8 58.0 23–153 61.9 21.3
Difference 15–79% (median 26%) 
p < 0.0001
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ferent epitopes of CgA molecule. As yet, an international 
standard for CgA assay is unavailable. Altogether, CgA 
measurements performed with the use of these assays 
are barely comparable and some of them are expressed in 
different units (a comparison of the selected methods used 
for CgA determination is presented in Table III). 
Some differences of CgA results might partly be 
caused also by the matrix effect related to the type of 
investigated biological material [6]. 
Some regions of the CgA molecule are homologues 
with calcium-binding protein - calmodulin. Therefore, 
CgA has a high capacity for calcium binding. In the 
presence of free Ca2+ CgA aggregate rapidly (the extent 
and rate of aggregation are highly dependent on Ca2+ 
concentration). Anticoagulation occurs through the 
binding of Ca2+ ions and the inhibition of thrombin 
action, whereas in venous blood samples drawn into 
tubes containing clot activator, the calcium ions remain 
free [7–10]. Partial aggregation of CgA in serum samples 
might explain the measured lower CgA concentration 
in serum than in plasma samples.
Such a possible explanation was considered by us after 
completing our previous study [11] in which, using two 
routinely used methods (IRMA and ELISA), we compared 
the results of CgA measurements performed in serum and 
plasma (EDTA2K) samples collected concomitantly from 
patients with various neuroendocrine tumours. 
In other studies, this problem of matrix effect in 
relation to CgA was not recognised. The reported up-
per reference values for the serum CgA concentration 
determined by IRMA method (manufactured by CIS-
bio) were as follows: Leon — 87 ng/mL [12], Ferrari— 
70 ng/mL [13], Stridsberg — 99 ng/mL [14]. The cited au-
thors did not declare that those values were valid only 
for the serum samples, while for instance, Stridsberg 
et al. measured CgA in heparinised plasma samples.
Bernini et al. [15] followed the manufacturer’s refer-
ence values established for serum samples and accepted 
this CgA value rounded up to 100 ng/mL for plasma 
samples. Ramachandran et al. [16] established the upper 
reference value at 94 ng/mL, but they calculated this value 
as the 85th percentile of 185 plasma (EDTA2K) samples of 
healthy patients and patients with non-NETs diseases.
We calculated due references ranges separately for 
the serum and plasma samples of 145 healthy males, 
expressed as 2.5 to 97.5 percentiles. Such a calculation 
seems to be more accurate because it covers a larger 
range of population. 
Figure 2. Correlation of CgA in serum and plasma (EDTA2K)
Rycina 2. Korelacja CgA w surowicy i w osoczu (EDTA2K)
Table II. Percentile distribution of CgA reference range in serum and plasma (EDTA2K)
Tabela II. Rozkład percentyli zakresu referencyjnego CgA w surowicy i w osoczu (EDTA2K)
CgA  Percentiles
  2.5th 5th 10th 25th 50th 75th 90th 95th 97.5th
Serum
Plasma 
(EDTA2K) 
21
31
25
 33
28
 39
 36
 48
42.5
58.5
54
72
 69
 98
81
105
 108
 153
Figure 1. The median and the ranges of CgA levels in serum and 
plasma (EDTA2K)
Rycina 1. Mediana oraz zakresy stężenia CgA w surowicy 
i w osoczu (EDTA2K)
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Using the IRMA (Cis bio) method, we obtained 
a very good correlation between CgA determination 
in serum and plasma. In one other study, the authors 
reported a low correlation (r = 0.61) between serum 
and plasma CgA concentration, which was probably 
because they correlated two different assays: the ELISA 
(DAKO) for plasma samples and IRMA (CIS bio) for 
serum samples [13].
In previous studies [17], no differences were found 
in CgA levels between men and women. In the latest 
study of Braga et al. [18], however, the authors showed 
that serum CgA concentrations were significantly 
higher in women than in men, but all values were below 
the cut-off value. 
A weak point of our work is a failure to collect 
a similarly large group of healthy females, which can be 
explained by the fact that most blood donors are males. 
Conclusions
1. Significant differences in the concentrations of CgA 
measured in plasma and in serum demand the ap-
plication of separate reference ranges adjusted to 
the type of investigated material.
2. Each laboratory should recommend only one sort 
of sample material for CgA assay. 
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Table III. Comparison of the currently available methods for determination of CgA concentration
Tabela III. Porównanie obecnie stosowanych metod oznaczania stężenia CgA
Method Immunoradiometric 
(IRMA)
ELISA ELISA Radioimmunoassay 
(RIA)
ELISA Automated 
immunometric 
assay (Kryptor)
Kit producer CISbio CISbio DAKO EuroDiagnostica ALPCO B.R.A.H.M.S.
Antibody 2 monoclonal 2 monoclonal 2 polyclonal 1 polyclonal 2 polyclonal 2 monoclonal
Standard  rh CgA rh CgA 23 kDa C-terminal 
fragment of CgA
CgA fraction purified 
from urine (patients  
with carcinoid tumours)
rh CgA rh CgA
Unit ng/mL ng/mL U/L nmol/L ng/mL μg/L
Sort of biological material 
(according to the kit 
producer)
Serum
Plasma
Serum
Plasma
Plasma (EDTA, 
heparin)
Serum
Plasma (EDTA, heparin)
Plasma (EDTA) Serum
Cut-off (according to the 
kit producer)
Serum 98 ng/mL
Plasma ?
Serum 98 ng/
mL
Plasma ?
Serum? 
Plasma 2–18 U/L
Serum and plasma  
≤ 3 nmol/L
Serum ? 
Plasma 100 ng/mL
Serum
Male: 84.7 μg/L
Female: 43.2 μg/L
Plasma ?
rh CgA — human recombinant CgA
